Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0368120220520070529
Korean Circulation Journal
2022 Volume.52 No. 7 p.529 ~ p.540
Long-Term Clinical Outcomes of Iliac Artery Endovascular Therapy in the Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA) Registry
Roh Ji-Woong

Shin Sang-Hoon
Ko Young-Guk
Son Nak-Hoon
Ahn Chul-Min
Min Pil-Ki
Lee Jae-Hwan
Yoon Chang-Hwan
Yu Cheol-Woong
Lee Seung-Whan
Lee Sang-Rok
Choi Seung-Hyuk
Chae In-Ho
Choi Dong-Hoon
Abstract
Background and Objectives: Limited data are available regarding long-term clinical outcomes of iliac artery endovascular therapy (EVT) in real-world practice. This study investigated long-term outcomes according to Trans-Atlantic Inter-Society Consensus (TASC) classifications.

Methods: We analyzed data from 1,705 limbs of 1,364 patients from the retrospective cohort of the multicenter Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Disease registry. The primary endpoint was target lesion revascularization (TLR)-free survival.

Results: TASC A, B, C, and D lesions were present in 19.4%, 26.2%, 28.7%, and 25.7% of the treated limbs, respectively. The technical success rate was 96.2% and did not differ between TASC lesion types. Complications occurred in 6.8% of cases and more occurred in TASC D (11.8%). Iliac artery EVT showed a 5-year TLR-free survival of 89.2%. The TASC D group had the lowest TLR-free rate of 79.3%. TASC D (hazard ratio [HR], 1.75; 95% confidence interval [CI], 1.12?2.73; p=0.014), plain old balloon angioplasty (HR, 4.25; 95% CI, 2.03?8.88; p<0.001), current smoker (HR, 1.89; 95% CI, 1.26?2.83; p=0.002), previous bypass surgery (HR, 3.04; 95% CI, 1.28?7.19; p=0.011), combined femoropopliteal treatment (HR, 4.89; 95% CI, 3.19?7.50; p<0.001), combined below the knee treatment (HR, 2.20; 95% CI, 1.25?3.89; p=0.007), and complications (HR, 1.86; 95% CI, 1.07?3.24; p=0.028) were predictors for TLR.

Conclusions: Iliac artery EVT achieved excellent technical success and 5-year TLR-free survival. TASC D showed a favorable but lower 5-year TLR-free survival rate and higher complication rate compared with other TASC groups.
KEYWORD
FullTexts / Linksout information
 
Listed journal information
SCI(E) ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø